Efficacy News and Research

RSS

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Moberg Derma AB has entered into a distribution agreement with OzHealth Pharma for Emtrix - for discolored and damaged nails caused by nail fungus or nail psoriasis.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

The new Montefiore Laser and Eye Center recently opened its doors to provide comprehensive care to Westchester patients at the Montefiore Medical Specialists of Westchester in Scarsdale, New York. Seven board-certified ophthalmologists from the Department of Ophthalmology and Visual Sciences at Montefiore Medical Center provide patients with specialty emphasis in pediatric ophthalmology, oculoplastic surgery, glaucoma, cornea and laser refractive surgery.

8 Jun 2011

FDA grants orphan drug designation for Edison's EPI-743 to treat inherited mitochondrial diseases

Edison Pharmaceuticals, Inc. announced today the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for treatment of inherited mitochondrial respiratory chain diseases.

8 Jun 2011

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher Pharmaceuticals Inc. today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

St. Jude Medical, Inc., a global medical device company, today announced the first human implant of its Portico transcatheter aortic heart valve. The procedure was performed by Dr. John Webb, director of cardiac catheterization and interventional cardiology at St. Paul's Hospital in Vancouver, British Columbia.

7 Jun 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Cyterix Pharmaceutics, Inc. announced today that the company has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues.

7 Jun 2011

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for the use of ivermectin topical cream as a treatment for head lice infestations in children and adults.

7 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

CWRU researcher helps combat mental illness in U.S. teens

When teens start experiencing changes in moods or emotions, they tend to fear sharing their blue days with their families and adults who can help them. As a consequence, they often suffer in silence.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

7 Jun 2011

Efficacy News and Research

NYU Cancer Institute scientists present new research findings at ASCO 2011

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Vaccine candidate produces immune response to antigen in all strains of influenza A

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

FDA grants orphan drug designation for Edison's EPI-743 to treat inherited mitochondrial diseases

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

CWRU researcher helps combat mental illness in U.S. teens

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Ovarian cancer screenings do not reduce risk of death

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News